We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Moderna Inc | NASDAQ:MRNA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.30 | 2.17% | 108.48 | 107.51 | 108.13 | 108.19 | 105.25 | 106.18 | 2,246,914 | 23:45:07 |
From Apr 2021 to Apr 2024
By Michael Dabaie
Moderna Inc. said it filed for authorization of its Covid-19 vaccine with Health Canada to include children ages 6 to 11.
The biotechnology company said it submitted for authorization with Health Canada for the evaluation of a 50 microgram two-dose series of Spikevax in children ages 6 to 11 years.
Moderna earlier this month filed to expand the conditional marketing authorization for its Covid-19 vaccine in the European Union to include children aged 6 to 11.
The Phase 2/3 KidCOVE study of the vaccine in pediatric population ages 6 months to under 12 years is continuing. Moderna recently shared data from the KidCOVE study in children 6 years to 11. Vaccine efficacy of 100% using the Phase 3 COVE study primary case definition for Covid-19 was observed two weeks after the first dose of Spikevax at the 50 ug dose level, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 17, 2021 08:54 ET (13:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Moderna Chart |
1 Month Moderna Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
